Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Anti-immunoglobulin E in the treatment of refractory atopic dermatitis.

Kim DH, Park KY, Kim BJ, Kim MN, Mun SK.

Clin Exp Dermatol. 2013 Jul;38(5):496-500. doi: 10.1111/j.1365-2230.2012.04438.x. Epub 2012 Oct 22.

PMID:
23083013
2.

Omalizumab treatment in severe adult atopic dermatitis.

Thaiwat S, Sangasapaviliya A.

Asian Pac J Allergy Immunol. 2011 Dec;29(4):357-60.

3.

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, McAlary M, Fowler-Taylor A, Racine A, Gupta N, Fick R, Della Cioppa G; Omalizumab Seasonal Allergic Rhinitis Trail Group.

JAMA. 2001 Dec 19;286(23):2956-67.

PMID:
11743836
4.

Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.

Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, Nadeau KC.

Int Arch Allergy Immunol. 2013;162(1):89-93. doi: 10.1159/000350486. Epub 2013 Jun 27.

5.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
6.

Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.

Holgate ST, Djukanović R, Casale T, Bousquet J.

Clin Exp Allergy. 2005 Apr;35(4):408-16. Review.

PMID:
15836747
7.

Anti-IgE--emerging opportunities for Omalizumab.

Babu KS, Polosa R, Morjaria JB.

Expert Opin Biol Ther. 2013 May;13(5):765-77. doi: 10.1517/14712598.2013.782391. Epub 2013 Mar 22. Review.

PMID:
23517576
8.

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.

Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P.

J Allergy Clin Immunol. 2011 Jul;128(1):202-209.e5. doi: 10.1016/j.jaci.2011.04.038. Epub 2011 Jun 2.

PMID:
21636116
9.

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K.

Allergy. 2004 Jul;59(7):709-17.

10.

Omalizumab. A review of the new treatment of allergic asthma and seasonal allergic rhinitis.

Félix Toledo R, Negro Alvarez JM, Miralles López JC.

Allergol Immunopathol (Madr). 2002 Mar-Apr;30(2):94-9. Review.

PMID:
11958741
11.

[Dermatological implications of omalizumab, an anti-IgE antibody].

Di Lucca-Chrisment J.

Rev Med Suisse. 2015 Apr 1;11(468):779-80, 782-3. French.

PMID:
26021140
12.

Anti-immunoglobulin e in the treatment of refractory atopic dermatitis.

Amrol D.

South Med J. 2010 Jun;103(6):554-8. doi: 10.1097/SMJ.0b013e3181de0cf6.

PMID:
20710140
13.

[Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].

Kupryś-Lipińska I, Kuna P.

Pneumonol Alergol Pol. 2009;77(1):43-51. Review. Polish.

14.

Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.

D'Amato G, Liccardi G, Noschese P, Salzillo A, D'Amato M, Cazzola M.

Curr Drug Targets Inflamm Allergy. 2004 Sep;3(3):227-9. Review.

PMID:
15379589
15.

Omalizumab in children.

Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S, Marseglia GL.

Paediatr Drugs. 2014 Dec;16(6):491-502. doi: 10.1007/s40272-014-0107-z. Review.

16.

Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).

Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM; QUALITX Study Investigators.

J Asthma. 2012 Apr;49(3):288-93. doi: 10.3109/02770903.2012.660297. Epub 2012 Feb 23.

PMID:
22356355
17.

Omalizumab for treatment of allergic rhinitis.

Vashisht P, Casale T.

Expert Opin Biol Ther. 2013 Jun;13(6):933-45. doi: 10.1517/14712598.2013.795943. Epub 2013 Apr 29. Review.

PMID:
23621175
18.

The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment.

Johansson SG, Nopp A, Oman H, Ankerst J, Cardell LO, Grönneberg R, Matsols H, Rudblad S, Strand V, Stålenheim G.

Allergy. 2009 Oct;64(10):1472-7. doi: 10.1111/j.1398-9995.2009.02051.x. Epub 2009 Apr 14.

19.

Anti-IgE for chronic asthma in adults and children.

Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH.

Cochrane Database Syst Rev. 2004;(3):CD003559. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD003559.

PMID:
15266491
20.

Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy.

Velling P, Skowasch D, Pabst S, Jansen E, Tuleta I, Grohé C.

Eur J Med Res. 2011 Sep 12;16(9):407-10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk